Helus Pharma (CYBN) interim CEO to join Milken Global Conference health innovation panel
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Cybin Inc., operating commercially as Helus Pharma, filed a Form 6-K to share a news release about an upcoming conference appearance and to describe its clinical pipeline. Interim CEO Eric So will speak on a Milken Institute Global Conference panel titled “The Next Wave of Health Innovation” on May 4, 2026, with a live and archived webcast available on the company’s investor relations site.
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) aimed at improving treatments for depression, anxiety and other mental health conditions. Lead candidate HLP003 is in Phase 3 development for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, while HLP004 is in Phase 2 for generalized anxiety disorder. The release includes extensive cautionary language, emphasizing that NSAs and the company’s product candidates have not been approved by regulators, their efficacy has not been confirmed, and further clinical research and regulatory approvals are required.
Positive
- None.
Negative
- None.
Key Figures
Conference dates: May 3-6, 2026
Panel date and time: May 4, 2026 at 2:30 p.m. PDT
HLP003 development stage: Phase 3
+1 more
4 metrics
Conference dates
May 3-6, 2026
Milken Institute Global Conference schedule
Panel date and time
May 4, 2026 at 2:30 p.m. PDT
Eric So Milken conference panel
HLP003 development stage
Phase 3
Adjunctive treatment of major depressive disorder
HLP004 development stage
Phase 2
Generalized anxiety disorder program
Key Terms
novel serotonergic agonists, Breakthrough Therapy Designation, Phase 3 clinical development, major depressive disorder, +2 more
6 terms
novel serotonergic agonists medical
"developing novel serotonergic agonists (“NSAs”), today announced"
Breakthrough Therapy Designation regulatory
"HLP003, a proprietary NSA, in Phase 3 clinical development ... that has received Breakthrough Therapy Designation"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
Phase 3 clinical development medical
"HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment"
major depressive disorder medical
"for the adjunctive treatment of major depressive disorder that has received"
A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.
generalized anxiety disorder medical
"HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder"
Generalized anxiety disorder is a chronic mental health condition marked by persistent, excessive worry about everyday things that is hard to control and interferes with daily life. Think of it like a smoke alarm that stays on for weeks or months, making work, decision-making and productivity harder; for investors it matters because it drives demand for treatments, affects workforce performance and can influence regulatory scrutiny, clinical trial design and healthcare spending.
forward-looking statements regulatory
"Certain statements in this news release relating to the Company are forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2026.
Commission File Number: 001-40673
Cybin Inc.
(Exact Name of Registrant as Specified in Charter)
100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CYBIN INC. | ||||||||||||||
| (Registrant) | ||||||||||||||
| Date: | April 30, 2026 | By: | /s/ Greg Cavers | |||||||||||
| Name: | Greg Cavers | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||
EXHIBIT INDEX
| 99.1 | News Release dated April 30, 2026 | ||||
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
•Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 2026
NEW YORK & TORONTO – April 30, 2026 – Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Eric So, Helus Pharma’s Interim Chief Executive Officer, will be speaking at the 29th Annual Milken Institute Global Conference on a panel entitled “The Next Wave of Health Innovation.” The Conference will take place May 3-6, 2026, at The Beverly Hilton & Waldorf Astoria in Los Angeles, and the panel will be held on Monday, May 4, 2026, at 2:30 p.m. PDT.
The live panel discussion and archived webcast will be available on the Company’s investor relations website on the Events & Presentations page. For more information on the Milken Institute and the upcoming conference visit www.milkeninstitute.org.
About Helus Pharma
Helus Pharma™, the commercial operating name of Cybin Inc. (the “Company” or “Helus Pharma”) is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs - novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus PharmaTM is a trademark of Cybin Corp.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2025, and the Company’s annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
Matthew.beck@astrpartners.com
George Tziras
Chief Business Officer
Helus Pharma
1-866-292-4601
irteam@helus.com – or – media@helus.com
Media Contact:
Johnny Tokarczyk
RXMD
Public Relations Director
jtokarczyk@rxmedyn.com
(914) 772-7562
FAQ
What does Cybin (Helus Pharma) disclose in this Form 6-K?
The filing shares a Helus Pharma news release about Interim CEO Eric So speaking at the Milken Institute Global Conference and provides an overview of the company’s NSA-based mental health pipeline, including Phase 3 and Phase 2 programs for depression and anxiety.
When and where will Helus Pharma’s CEO speak at the Milken Institute Global Conference?
Eric So, Helus Pharma’s Interim CEO, will speak on a panel titled “The Next Wave of Health Innovation” at the Milken Institute Global Conference on May 4, 2026, at 2:30 p.m. PDT, held at The Beverly Hilton & Waldorf Astoria in Los Angeles.
What mental health drugs is Cybin’s Helus Pharma currently developing?
Helus Pharma is developing proprietary novel serotonergic agonists. Lead candidate HLP003 is in Phase 3 for adjunctive treatment of major depressive disorder, and HLP004 is in Phase 2 for generalized anxiety disorder, alongside a broader research portfolio of investigational NSA compounds targeting mental health conditions.
Has the FDA approved Helus Pharma’s NSAs, HLP003, or HLP004?
No regulatory authority has approved Helus Pharma’s NSAs, HLP003, or HLP004. The company notes their efficacy has not been confirmed by approved research, and rigorous scientific studies and clinical trials, plus regulatory approvals, are still required before any commercialization is possible.
What is notable about HLP003 in Cybin’s Helus Pharma pipeline?
HLP003 is described as a proprietary novel serotonergic agonist in Phase 3 clinical development for adjunctive treatment of major depressive disorder. It has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, signaling regulatory recognition of its potential based on early clinical data.
Where does Helus Pharma operate and under what commercial name does Cybin trade?
Cybin Inc. operates commercially as Helus Pharma and reports operations in Canada, the United States, the United Kingdom, and Ireland. The Helus brand focuses on developing proprietary novel serotonergic agonists intended to address significant unmet needs in depression, anxiety, and other mental health disorders.